GLP-1 Market
LLY $1188.72 ▲ +2.7% NVO $38.26 ▲ +1.9% PFE $28.00 ▲ +1.8% VKTX $28.54 ▲ +0.6% KLRA $10.53 ▼ -2.8% GPCR $26.68 ▼ -2.9% RHHBY $53.97 ▲ +2.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LY3549492

LY3549492

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 8, 2026

Find a Clinical Trial Near Me

See recruiting studies for LY3549492 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06143956

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 1481 participants Est. completion 2028-02 57 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT04758234

    A Study of LY3549492 in Healthy Participants

    Not yet reported Eli Lilly and Company 54 participants Est. completion 2022-01-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05327595

    A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Eli Lilly and Company 80 participants Est. completion 2024-04-22 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06194500

    A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

    Not yet reported Eli Lilly and Company 18 participants Est. completion 2024-02-15 1 site Stand-alone
    Other conditions: Healthy Male
    View official trial listing →
  • Completed NCT NCT06683508

    A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 288 participants Est. completion 2026-05-04 49 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT06869018

    A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants

    Not yet reported Eli Lilly and Company 92 participants Est. completion 2026-03-02 4 sites Stand-alone
    Type 2 diabetes Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT07030868

    A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 1 participants Est. completion 2025-07-29 42 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT07073170

    A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 36 participants Est. completion 2026-01-27 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT07085468

    A Study of LY3549492 in Healthy Weight Adult Participants

    Not yet reported Eli Lilly and Company 1 participants Est. completion 2025-08-14 21 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT07232732

    A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

    Not yet reported Eli Lilly and Company 120 participants Est. completion 2026-07-16 3 sites Stand-alone
    Other conditions: Healthy, Obesity, Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.